Adding Linezolid to Standard Antibiotics for Adults With Staphylococcus Aureus Bloodstream Infection A Randomized Controlled Study
Led by University Hospital, Basel, Switzerland · Updated on 2026-07-13
606
Participants Needed
12
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Staphylococcus aureus bloodstream infections are serious and deadly, with high mortality and complications despite available antibiotics. Researchers are evaluating whether adding linezolid, an antibiotic known to inhibit bacterial toxins, to standard treatment can improve outcomes in these infections. This randomized controlled trial aims to test if targeting bacterial virulence factors with linezolid benefits patients with S. aureus bacteraemia.
Participants receive either linezolid 600 mg tablets twice daily for 5 days or matching placebo tablets, both alongside standard antibiotic treatment. This is a placebo-controlled, randomized trial designed to assess the additional effect of linezolid when combined with usual care. The treatment period is five days, followed by observation until day 90 to evaluate outcomes.
During the study, participants are monitored from the day of randomization through day 90 for clinical outcomes using a Desirability of Outcome Ranking DOOR measure. Researchers collect data on mortality, function, microbiological results, hospital stay, antibiotic use, and safety events, including adverse reactions and laboratory assessments. The study involves detailed follow-up visits and assessments focusing on both efficacy and safety over a three-month period.
CONDITIONS
Brief Title
Linezolid Plus Standard of Care
Research Team
R
Richard Kühl, PD Dr. med.
N
Natalie Rose, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Staphylococcus aureus grown from at least one blood culture
Hospitalised at a participating centre
18 years old or older
Provided written informed consent or meet criteria for emergency exception from consent
You will not qualify if you...
Initial drug treatment cannot start within 72 hours of first positive S. aureus blood culture
History of positive S. aureus blood cultures 72 hours to 180 days before screening
Necrotising fasciitis
Currently receiving linezolid or clindamycin
Use of any monoamine oxidase A or B inhibitor in last two weeks
Known allergy to linezolid or study drug ingredients
Severe thrombocytopenia (platelets below 30 x 10^9/L)
Unable to take study drug orally or via gastric tube
Currently breastfeeding
Imminent and inevitable death according to treating team
Receiving end of life care with no antibiotic treatment
Participation not considered in patient’s best interest by treating team
Patient unwilling to participate or has advance directive refusing participation
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - 5 days
Participants receive linezolid 600 mg tablets or placebo twice daily for 5 days, alongside standard antibiotic treatment.
Twice daily dosing for 5 days
Follow-up
Duration - Up to 90 days
Participants are monitored for clinical outcomes, function, microbiological results, safety events, and hospital stay until day 90 after randomization.
Regular assessments during follow-up period
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Clinical Trial Comparing Benzylpenicillin and Cloxacillin Treatments for Adults with Penicillin-Susceptible Staphylococcus Aureus Bloodstream Infection
Adding Linezolid to Standard Antibiotics for Adults With Staphylococcus Aureus Bloodstream Infection A Randomized Controlled Study
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Linezolid in addition to standard antibiotic treatment for Staphylococcus aureus bacteraemia: study protocol for a randomised, placebo-controlled trial.
Natalie Rose, Nadine S Bernasconi, Michaela Schumacher...